[1]De Vries L, Zheng B, Fischer T, et al. The regulator of G protein signaling family[J]. Annu Rev Pharmacol Toxicol, 2000, 40(2):235-271. [2]Tang M, Wang G, Lu P, et al. Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure[J]. Nat Med, 2003, 9(4):1506-1512.[3]Heximer SP, Knutsen RH, Sun XG, et al. Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice[J]. J Clin Invest, 2003, 111(7):445-452.[4]Ross DF, Gyros R. Regulator of G-protein signaling-2 as a candidate gene: the road to hypertension or just another roadside marker[J].Hypertension, 2006, 47(6):337-338. [5]Steven Gu, Sam Tirgari S, Heximer SP. The RGS2 gene product from a candidate hypertension allele shows decreased plasma membrane association and inhibition of Gq [J]. Pharmacol, 2008, 73(9):1037-1043.[6]Yang J, Kamide K, Kokubo Y, et al. Genetic variations of regulator of G-protein signaling 2 in hypertensive patients in the general population[J]. J Hypertens,2005, 23(7):1497-1505.[7]Evan L, Brinda KR, Kenton KM, et al. Polymorphisms and haplotypes of the regulator of G protein signaling-2 gene[J]. Hypertension, 2006, 47(5):415-420.[8]Cohen JC, Kiss RS, Pertsemlidis A, et al. Multiple rare alleles contribute to low plasma levels of HDL cholesterol [J]. Science, 2004, 305(5685):869-872.[9]Ng SB, Turner EH, Robertson PD, et al. Targeted capture and massively parallel sequencing of 12 human exons [J]. Nature, 2009, 461(7261):272-276.[10]Bodenstein J, Sunahara RK, Neubing RR. N-terminal residues control proteasomal degradation of RGS2, RGS4 and RGS5 in human embryonic kidney cell[J]. MOL Pharmacol, 2007, 71(2):1040-1050. |